Fennec Pharmaceuticals Inc (FENC)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Rostislav C. Raykov
Employees:
10
PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC 27709
(919) 636-4530

Fennec Pharmaceuticals Inc. develops product candidates for use in the treatment of cancer in the U.S. Its lead product PEDMARK is a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Data derived from most recent annual or quarterly report
Market Cap 182.281 Million Shares Outstanding26.059 Million Avg 30-day Volume 33.394 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.15
Price to Revenue0.0 Debt to Equity-0.0008 EBITDA-17.242 Million
Price to Book Value7.255 Operating Margin0.0 Enterprise Value93.314 Million
Current Ratio13.535 EPS Growth0.118 Quick Ratio12.757
1 Yr BETA 0.5432 52-week High/Low 10.08 / 3.82 Profit Margin0.0
Operating Cash Flow Growth8.8041 Altman Z-Score-2.3051 Free Cash Flow to Firm -7.963 Million
Earnings Report2022-08-10
View SEC Filings from FENC instead.

View recent insider trading info

Fennec Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding FENC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FENC

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-07-18 by RALLIS CHRIS A
  • 4: filed on 2022-06-16 by RALLIS CHRIS A
  • 4: filed on 2022-06-16 by ISLAM KHALID
  • 4: filed on 2022-06-16 by HAIGH ADRIAN
  • 4: filed on 2022-06-16 by COOK JODI A
  • 4: filed on 2022-06-16 by BRUGHERA MARCO MARIA
  • 4: filed on 2022-03-08 by RALLIS CHRIS A
  • 4: filed on 2021-12-20 by GOEL SHUBH
  • 4: filed on 2021-12-20 by ANDRADE ROBERT
  • 4: filed on 2021-12-20 by RAYKOV ROSTY

    • Events (8k)

  • 8-K: filed on 2022-08-01:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-15:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-03-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-30:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-30:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-06-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-05-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-10-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    11.1 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RALLIS CHRIS A

    • Director
    		 27,657 2022-07-18 4

    BRUGHERA MARCO MARIA

    • Director
    		 20,000 2022-06-14 1

    ISLAM KHALID

    • Director
    		 25,000 2022-06-14 1

    HAIGH ADRIAN

    • Director
    		 20,000 2022-06-14 1

    COOK JODI A

    • Director
    		 20,000 2022-06-14 1

    ANDRADE ROBERT CHIEF FINANCIAL OFFICER

    • Officer
    		 112,500 2021-12-20 1

    RAYKOV ROSTY CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 300,000 2021-12-20 1

    GOEL SHUBH CHIEF COMMERCIAL OFFICER

    • Officer
    		 112,500 2021-12-20 1

    SOUTHPOINT CAPITAL ADVISORS LP

    SOUTHPOINT CAPITAL ADVISORS LLC

    SOUTHPOINT GP, LP

    SOUTHPOINT GP, LLC

    CLARK JOHN SMITH II

    • 10% Owner
    		 4,077,214 2020-05-04 0

    ESSETIFIN SPA

    CAVAZZA PAOLO

    CAVAZZA ENRICO

    CAVAZZA FRANCESCA

    CAVAZZA SILVIA

    CAVAZZA PRETA MARTINA

    • 10% Owner
    		 3,993,694 2020-04-30 0

    ESSETIFIN SPA

    • 10% Owner
    		 2,931,579 2017-09-11 0

    SOUTHPOINT MASTER FUND, LP

    • 10% Owner
    		 3,997,214 2017-09-11 0

    MANCHESTER MANAGEMENT PR, LLC

    MANCHESTER MANAGEMENT CO LLC

    MANCHESTER EXPLORER, L.P.

    BESSER JAMES E

    FRANK MORGAN C.

    • 10% Owner
    		 No longer subject to file 2016-01-27 0

    MANCHESTER MANAGEMENT PR, LLC

    • 10% Owner
    		 2,017,357 2016-01-01 0

    MANCHESTER MANAGEMENT CO LLC

    MANCHESTER EXPLORER, L.P.

    BESSER JAMES E

    FRANK MORGAN C.

    • 10% Owner
    		 3,508,831 2014-08-29 0

    BREEN WILLIAM G

    • Director
    		 1,367,781 2010-08-18 0

    BUSSANDRI CLAUDIO F

    • Director
    		 0 2010-08-18 0

    SPECTOR THOMAS NA

    • Officer
    		 0 2010-08-18 0

    PORTER ARTHUR T

    • Director
    		 0 2010-08-17 0

    LIEBERMAN DAVID B.

    • Director
    		 0 2010-06-24 0

    BUTTS ROBERT W CHAIRMAN OF BOARD

    • Officer
    • Director
    • 10% Owner
    		 41,504,000 2010-06-08 0

    NORRIS ROBIN J PRESIDENT

    • Officer
    		 0 2009-11-16 0

    MERMELSTEIN FRED H

    • Director
    		 75,000 2007-12-03 0

    PETERS WILLIAM P CHAIRMAN AND CEO

    • Officer
    • Director
    		 1,000,000 2007-12-03 0

    MURRAY D SCOTT SVP, GEN COUNSEL & CORP SECTY

    • Officer
    		 1,544,470 2007-12-03 0

    KLEIN JAMES A JR CFO

    • Officer
    		 1,522,500 2007-12-03 0

    MORAND PETER

    • Director
    		 519,042 2007-12-03 0

    KUFE DONALD W

    • Director
    		 380,742 2007-12-03 0

    MARTIN MICHAEL G

    • Director
    		 310,000 2007-12-03 0

    SOLASH JEFFREY CHIEF LICENSING OFFICER

    • Officer
    		 0 2007-02-21 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    RALLIS CHRIS A - Director

    		2022-07-18 18:00:39 -0400 2022-07-18 M 11,111 $0.45 a 32,036 direct 1.5244 1.5244 6.0976 5 0.0 1

    RALLIS CHRIS A - Director

    		2022-07-18 18:00:39 -0400 2022-07-18 F 4,379 $6.70 d 27,657 direct 1.5244 1.5244 6.0976 5 0.0 1

    BRUGHERA MARCO MARIA - Director

    		2022-06-16 09:21:21 -0400 2022-06-14 A 20,000 a 20,000 direct

    COOK JODI A - Director

    		2022-06-16 09:22:21 -0400 2022-06-14 A 20,000 a 20,000 direct

    HAIGH ADRIAN - Director

    		2022-06-16 09:23:45 -0400 2022-06-14 A 20,000 a 20,000 direct

    RALLIS CHRIS A - Director

    		2022-06-16 09:26:31 -0400 2022-06-14 A 20,000 a 20,000 direct

    ISLAM KHALID - Director

    		2022-06-16 09:24:58 -0400 2022-06-14 A 25,000 a 25,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 22:15:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 21:45:03 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 21:15:03 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 20:45:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 20:15:05 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 19:45:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 19:15:05 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 18:45:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 18:15:03 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 17:45:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 17:15:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 16:45:05 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 16:15:05 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 15:45:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 15:15:03 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 14:45:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 14:15:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 13:45:05 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 13:15:04 UTC 0.4258 1.8942 750000
    FENNEC PHARMACEUTICALS INC FENC 2022-08-05 12:45:05 UTC 0.4258 1.8942 750000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund FENC -1200.0 shares, $-6720.0 2022-03-31 N-PORT

    Elevate your investments